MLAB (Mesa Laboratories) Cyclically Adjusted Revenue per Share: $38.92 (As of Mar. 2026)


MLAB Mesa Laboratories Inc MLAB
77 GF Score
Price $104.27
GF Value $116.15
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Mesa Laboratories Cyclically Adjusted Revenue per Share?

Mesa Laboratories MLAB -0.12% 77 Cyclically Adjusted Revenue per Share is $38.92 as of Mar. 2026. GuruFocus rates MLAB with a GF Score™ of 77/100 and a GF Value™ of $116.15 (Modestly Undervalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Mesa Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was $11.371. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $38.92 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Mesa Laboratories's average Cyclically Adjusted Revenue Growth Rate was 7.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Mesa Laboratories was 17.90% per year. The lowest was 7.50% per year. And the median was 13.00% per year.

As of today (2026-07-02), Mesa Laboratories's current stock price is $104.265. Mesa Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $38.92. Mesa Laboratories's Cyclically Adjusted PS Ratio of today is 2.68.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mesa Laboratories was 13.88. The lowest was 1.66. And the median was 9.12.


Mesa Laboratories  (NAS:MLAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Mesa Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=104.265/38.92
=2.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mesa Laboratories was 13.88. The lowest was 1.66. And the median was 9.12.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Mesa Laboratories Cyclically Adjusted Revenue per Share Related Terms


Mesa Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Mesa Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesa Laboratories Cyclically Adjusted Revenue per Share Chart

Mesa Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.69 30.49 33.68 36.32 38.92

Mesa Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.32 37.05 37.61 37.98 38.92

MLAB vs AERG, USBC, MVIS: Cyclically Adjusted Revenue per Share Comparison

For the Scientific & Technical Instruments subindustry, Mesa Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mesa Laboratories Cyclically Adjusted PS Ratio vs Hardware Industry

For the Hardware industry and Technology sector, Mesa Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Mesa Laboratories's Cyclically Adjusted PS Ratio falls into.


MLAB
77GF Score
Mesa Laboratories Inc MLAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesa Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Mesa Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=11.371/330.2130*330.2130
=11.371

Current CPI (Mar. 2026) = 330.2130.

Mesa Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 5.553 241.018 7.608
201609 6.371 241.428 8.714
201612 6.164 241.432 8.431
201703 6.277 243.801 8.502
201706 5.780 244.955 7.792
201709 5.833 246.819 7.804
201712 6.261 246.524 8.386
201803 7.102 249.554 9.397
201806 6.276 251.989 8.224
201809 6.146 252.439 8.040
201812 6.596 251.233 8.670
201903 6.577 254.202 8.544
201906 6.434 256.143 8.295
201909 5.910 256.759 7.601
201912 7.249 256.974 9.315
202003 7.821 258.115 10.006
202006 6.413 257.797 8.214
202009 6.079 260.280 7.712
202012 6.668 260.474 8.453
202103 6.625 264.877 8.259
202106 6.587 271.696 8.006
202109 6.707 274.310 8.074
202112 10.452 278.802 12.379
202203 11.024 287.504 12.662
202206 9.568 296.311 10.663
202209 10.952 296.808 12.185
202212 10.128 296.797 11.268
202303 10.329 301.836 11.300
202306 9.428 305.109 10.204
202309 9.869 307.789 10.588
202312 9.910 306.746 10.668
202403 10.924 312.332 11.549
202406 10.725 314.175 11.272
202409 10.571 315.301 11.071
202412 11.575 315.605 12.111
202503 11.411 319.799 11.783
202506 10.723 322.561 10.977
202509 10.973 324.800 11.156
202512 11.703 324.054 11.925
202603 11.371 330.213 11.371

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $38.92 mean?
Mesa Laboratories (MLAB) has a Cyclically Adjusted Revenue per Share of $38.92 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mesa Laboratories and its competitors.
Is Mesa Laboratories' Cyclically Adjusted Revenue per Share too high?
Mesa Laboratories' current Cyclically Adjusted Revenue per Share is $38.92. Overall, Mesa Laboratories has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mesa Laboratories' Cyclically Adjusted Revenue per Share compare to AERG and USBC?
Mesa Laboratories' Cyclically Adjusted Revenue per Share of $38.92 can be compared against companies in the Hardware industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Hardware company?
A good Cyclically Adjusted Revenue per Share depends on the Hardware industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mesa Laboratories and its competitors. Mesa Laboratories's current Cyclically Adjusted Revenue per Share is $38.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesa Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Mesa Laboratories (MLAB) is currently considered Modestly Undervalued. The stock's GF Value™ is $116.15, compared to a current price of $104.27 — trading 10.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $38.92. Mesa Laboratories' overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Mesa Laboratories (MLAB), the current Cyclically Adjusted Revenue per Share is $38.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mesa Laboratories (MLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Mesa Laboratories stock appears to be undervalued. The current stock price of $104.27 is trading 10.2% below its estimated GF Value™ of $116.15. GuruFocus considers Mesa Laboratories to be Modestly Undervalued.

Key valuation signals for MLAB:

  • Cyclically Adjusted Revenue per Share: $38.92
  • GF Value™: $116.15 vs. price of $104.27 (10.2% below fair value)
  • GF Score™: 77/100 with 8 warning signs

No single metric tells the full story. See the MLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mesa Laboratories Business Description

Address 12100 West Sixth Avenue, Lakewood, CO, USA, 80228
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
77GF Score

Get the complete analysis for MLAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$104.27
Price
$116.15
GF Value